{
    "2014-12-03": [
        "AMGN Blincyto FDA accelerated app'l on P2 r/r adult ALL trial; 1' endpt=CR+CRh* rate (43%; mOS 6.1mo at ASCO2014) biotech leukemia",
        "Nasdaq100 Stocks Performance TRIP BIIB ALXN NFLX REGN STX MXIM QCOM VRTX MU AMGN GILD SPLS",
        "AMGN - FDA Approves BLINCYTOâ„¢ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory"
    ]
}